BR112014021897A2 - nova fusão fgfr3 - Google Patents

nova fusão fgfr3

Info

Publication number
BR112014021897A2
BR112014021897A2 BR112014021897A BR112014021897A BR112014021897A2 BR 112014021897 A2 BR112014021897 A2 BR 112014021897A2 BR 112014021897 A BR112014021897 A BR 112014021897A BR 112014021897 A BR112014021897 A BR 112014021897A BR 112014021897 A2 BR112014021897 A2 BR 112014021897A2
Authority
BR
Brazil
Prior art keywords
gene
fgfr3
fusion
probe set
polynucleotide
Prior art date
Application number
BR112014021897A
Other languages
English (en)
Other versions
BR112014021897B1 (pt
Inventor
Morinaka Akifumi
Suzuki Atsushi
Yoshizaki Hiroaki
Tsunoyama Kazuhisa
Nishimura Kouichi
Asaumi Makoto
Yoshino Masayasu
Yamauchi Tomohiro
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49116820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014021897(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR112014021897A2 publication Critical patent/BR112014021897A2/pt
Publication of BR112014021897B1 publication Critical patent/BR112014021897B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Abstract

resumo “nova fusão fgfr3” a presente invenção visa elucidar um polinucleotídeo como um gene responsável inovador para câncer e visa prover um método para detectar o polinucleotídeo e um polipeptídeo codificado pelo polinucleotídeo e um kit de detecção, um conjunto de sonda, e um conjunto de iniciadores para a detecção. a presente invenção também visa prover uma composição farmacêutica para tratamento de câncer. o método detecta um gene de fusão composto por uma porção de um gene fgfr3 e uma porção de um gene tacc3 ou uma proteína de fusão codificada pelo gene de fusão. o conjunto de iniciadores, o conjunto de sondas, ou o kit de detecção compreendem um iniciador senso e um conjunto de sondas designado a partir da porção que codifica fgfr3 e um iniciador anti-senso e um conjunto de sondas designado a partir da porção que codifica tacc3. visto que um inibidor do polipeptídeo exibe um efeito antitumoral, uma composição farmacêutica para tratar câncer que seja positivo para o gene de fusão ou para o polipeptídeo é provida.
BR112014021897-8A 2012-03-08 2013-03-07 Método, kit, conjunto de iniciadores e conjuntos de sondas para detectar um gene de fusão composto por um gene fgfr3 e um gene tacc3 BR112014021897B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2012052147 2012-03-08
JP2012-052147 2012-03-08
JP2012-195451 2012-09-05
JP2012195451 2012-09-05
JP2012-280325 2012-12-21
JP2012280325 2012-12-21
PCT/JP2013/056225 WO2013133351A1 (ja) 2012-03-08 2013-03-07 新規ｆｇｆｒ３融合体

Publications (2)

Publication Number Publication Date
BR112014021897A2 true BR112014021897A2 (pt) 2017-07-11
BR112014021897B1 BR112014021897B1 (pt) 2022-06-14

Family

ID=49116820

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021897-8A BR112014021897B1 (pt) 2012-03-08 2013-03-07 Método, kit, conjunto de iniciadores e conjuntos de sondas para detectar um gene de fusão composto por um gene fgfr3 e um gene tacc3

Country Status (17)

Country Link
US (2) US9481911B2 (pt)
EP (1) EP2824181B1 (pt)
JP (1) JP6107812B2 (pt)
KR (4) KR20200046135A (pt)
CN (1) CN104379740B (pt)
AU (1) AU2013228389A1 (pt)
BR (1) BR112014021897B1 (pt)
CA (1) CA2865388C (pt)
EA (1) EA029140B1 (pt)
ES (1) ES2702305T3 (pt)
HK (1) HK1205528A1 (pt)
MX (1) MX365214B (pt)
PH (1) PH12014501918A1 (pt)
PL (1) PL2824181T3 (pt)
PT (1) PT2824181T (pt)
WO (1) WO2013133351A1 (pt)
ZA (1) ZA201406570B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
AU2013295805B2 (en) * 2012-07-24 2019-05-02 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
JP6117222B2 (ja) 2012-09-27 2017-04-19 中外製薬株式会社 Ｆｇｆｒ３融合遺伝子およびそれを標的とする医薬
WO2014071419A2 (en) * 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
US20160052926A1 (en) * 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
WO2014165710A2 (en) * 2013-04-05 2014-10-09 Life Technologies Corporation Gene fusions
TW201605452A (zh) * 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
EP3085781A1 (en) * 2013-12-19 2016-10-26 National Cancer Center Novel fusion gene as factor responsible for stomach cancer
US10048277B2 (en) 2014-01-24 2018-08-14 Japanese Foundation For Cancer Research Method for detecting an FGFR3/TACC3 fusion protein, or encoding gene thereof
EP3102705A4 (en) * 2014-02-04 2017-10-25 Mayo Foundation for Medical Education and Research Method of identifying tyrosine kinase receptor rearrangements in patients
JP6980385B2 (ja) 2014-03-26 2021-12-15 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP6524833B2 (ja) * 2015-07-17 2019-06-05 コニカミノルタ株式会社 蛍光体集積ナノ粒子を用いたｆｉｓｈまたは免疫染色スライドの封入方法
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
CN111424081B (zh) * 2020-04-13 2023-04-25 广东省妇幼保健院 基于多重荧光定量pcr技术检测软骨发育不全fgfr3基因突变的引物、探针和试剂盒
AR123306A1 (es) 2020-08-21 2022-11-16 Genzyme Corp Anticuerpos fgfr3 y métodos de uso

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1878766B (zh) * 2003-11-07 2011-08-17 诺华疫苗和诊断公司 合成喹啉酮化合物的方法
JP4724665B2 (ja) 2003-11-07 2011-07-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キノリノン化合物を合成する方法
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
AR078411A1 (es) 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
US20130096021A1 (en) 2011-09-27 2013-04-18 Arul M. Chinnaiyan Recurrent gene fusions in breast cancer
CN104144915B (zh) 2012-02-28 2016-08-24 安斯泰来制药有限公司 含氮芳香族杂环化合物
AU2013295805B2 (en) * 2012-07-24 2019-05-02 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
JP6117222B2 (ja) 2012-09-27 2017-04-19 中外製薬株式会社 Ｆｇｆｒ３融合遺伝子およびそれを標的とする医薬
WO2014071419A2 (en) * 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof

Also Published As

Publication number Publication date
ZA201406570B (en) 2015-12-23
KR20200046135A (ko) 2020-05-06
ES2702305T3 (es) 2019-02-28
PL2824181T3 (pl) 2019-02-28
JP6107812B2 (ja) 2017-04-05
BR112014021897B1 (pt) 2022-06-14
US9481911B2 (en) 2016-11-01
US20160375023A1 (en) 2016-12-29
EA201491655A1 (ru) 2015-01-30
CN104379740B (zh) 2019-05-14
PT2824181T (pt) 2018-12-20
WO2013133351A1 (ja) 2013-09-12
JPWO2013133351A1 (ja) 2015-07-30
US20150031703A1 (en) 2015-01-29
KR20140140070A (ko) 2014-12-08
HK1205528A1 (en) 2015-12-18
PH12014501918A1 (en) 2014-11-24
EP2824181A4 (en) 2015-07-15
MX2014010823A (es) 2015-03-19
EA029140B1 (ru) 2018-02-28
US10004739B2 (en) 2018-06-26
KR20220017512A (ko) 2022-02-11
EP2824181B1 (en) 2018-11-14
CA2865388C (en) 2022-01-04
MX365214B (es) 2019-05-27
CA2865388A1 (en) 2013-09-12
CN104379740A (zh) 2015-02-25
KR20230111270A (ko) 2023-07-25
EP2824181A1 (en) 2015-01-14
AU2013228389A1 (en) 2014-09-25
KR102106962B1 (ko) 2020-05-07

Similar Documents

Publication Publication Date Title
BR112014021897A2 (pt) nova fusão fgfr3
BR112016004415A2 (pt) método de tratamento de um paciente diagnosticado com um glioblastoma, uso de uma quantidade eficaz de um anticorpo anti-vegf, composição e kit
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
BR112015001054A8 (pt) Helicase monomérica que é membro da superfamília 1 ou superfamília 2, helicase hel308 isolada, método para caracterizar um polinucleotídeo alvo, e, sensor para a caracterização de um polinucleotídeo alvo
MX2016017296A (es) Sintasa del acido cannabicromenico proveniente de cannabis sativa.
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
BR112017004056A2 (pt) composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
WO2014124339A3 (en) Use of translational profiling to identify target molecules for therapeutic treatment
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
WO2018136919A3 (en) Methods relating to lung cancer
BR112012013635A2 (pt) método utilizável com um poço, e sistema utilizável com um poço.
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas
BR112018004207A2 (pt) biomarcadores e métodos de tratamento de câncer
BR112015022825A2 (pt) métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
BR112015020054A2 (pt) Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
WO2015077342A3 (en) Detection of arginine methylation of egfr for prediction of resistance to therapy
EA201501137A1 (ru) Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2013, OBSERVADAS AS CONDICOES LEGAIS